文献速递糖尿病

速效门冬胰岛素与门冬胰岛素在成人1型糖尿病第二代混合闭环系统中的随机交叉试验

Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial.
PubMed 文献 · Diabetes Care · 2021-01-01

P=0.007),4小时餐后TIR也更高(73.6% vs 72.1%,中位差异3.5%,P=0.003)。无酮症酸中毒或严重低血糖发生。

要点

  • 在AHCL系统中,faster aspart较IAsp略微提高整体TIR(82.3% vs 79.6%)。
  • 餐后4小时TIR改善更明显(73.6% vs 72.1%),主要源于餐时血糖。
  • TIR差异仅1.9%,临床影响可能较小,但安全性良好。

核心结论

  • 在血糖控制良好的成人1型糖尿病中,使用AHCL系统时faster aspart安全且小幅改善血糖控制,主要与餐时血糖相关。

研究设计与样本

  • 阶段1和2各为6周闭环,之前2周开环;阶段3直接换回阶段1的胰岛素制剂闭环1周。
  • 参与者自行选择餐食,但包含两次标准化餐食测试(漏餐大剂量和延迟餐食大剂量)。

主要发现

  • faster aspart整体TIR为82.3%(78.5-83.7),IAsp为79.6%(77.0-83.4),平均差异1.9%(0.5-3.3),P=0.007。
  • 所有餐食合并的4小时餐后TIR,faster aspart为73.6%(69.4-80.2),IAsp为72.1%(64.5-78.5),中位差异3.5%(1.0-7.3),P=0.003。
  • 未发生酮症酸中毒或严重低血糖。

临床怎么用

  • 对于使用AHCL系统的成人1型糖尿病,可考虑faster aspart以小幅改善餐时血糖和整体TIR。
  • 需权衡TIR改善幅度(1.9%)与临床意义,个体化选择胰岛素制剂。

局限性

  • 参与者血糖控制良好(中位HbA1c 7.0%),结果可能不适用于控制较差者。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate glucose control using fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp) delivered by the MiniMed Advanced Hybrid Closed-Loop (AHCL) system in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this randomized, open-label, crossover study, participants were assigned to receive faster aspart or IAsp in random order. Stages 1 and 2 comprised of 6 weeks in closed loop, preceded by 2 weeks in open loop. This was followed by stage 3, whereby participants changed directly back to the insulin formulation used in stage 1 for 1 week in closed loop. Participants chose their own meals except for two standardized meal tests, a missed meal bolus and late meal bolus. The primary outcome was the percentage of time sensor glucose values were from 70 to 180 mg/dL (time in range [TIR]). RESULTS: Twenty-five adults (52% male) were recruited; the median (interquartile range) age was 48 (37, 57) years, and the median HbA1c was 7.0% (6.6, 7.2) (53 [49, 55] mmol/mol). Faster aspart demonstrated greater overall TIR compared with IAsp (82.3% [78.5, 83.7] vs. 79.6% [77.0, 83.4], respectively; mean difference 1.9% [0.5, 3.3]; P = 0.007). Four-hour postprandial glucose TIR was higher using faster aspart compared with IAsp for all meals combined (73.6% [69.4, 80.2] vs. 72.1% [64.5, 78.5], respectively; median difference 3.5% [1.0, 7.3]; P = 0.003). There was no ketoacidosis or severe hypoglycemia. CONCLUSIONS: Faster aspart safely improved glucose control compared with IAsp in a group of adults with well-controlled type 1 diabetes using AHCL. The modest improvement was mainly related to mealtime glycemia. While the primary outcome demonstrated statistical significance, the clinical impact may be small, given an overall difference in TIR of 1.9%.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lee MH, Paldus B, Vogrin S, et al. Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. Diabetes Care. 2021. PMID: 34362816. doi:10.2337/dc21-0814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。